ODINSIGNAL JOURNAL · NEWS & EVENTS
FDA decision on BBP-418 for muscular dystrophy slated for Nov 27 2026
BridgeBio Pharma’s BBP-418 (ribitol) has a PDUFA target date of November 27 2026 for Limb Girdle Muscular Dystrophy Type 2i.
At a glance
- Date
- 2026-11-27
BridgeBio Pharma’s ribitol candidate BBP-418 is under FDA review for Limb Girdle Muscular Dystrophy Type 2i. The agency’s PDUFA calendar lists a target decision date of November 27 2026 for this application. The deadline is set by the FDA and may shift if the agency issues an extension or requests additional data.
On that day the FDA will either grant approval or issue a Complete Response Letter outlining required changes. The outcome will be closely watched by patients, clinicians, and investors interested in this rare‑disease therapy.
Follow the event on OdinSignal.
FOLLOW THE EVENT
What happens next?
Explore the event, review its rules, and share your prediction on OdinSignal.
Explore the prediction market →Virtual credits only. No cash value.More from the Journal
Summit Therapeutics’ ivonescimab receives FDA PDUFA goal date of Nov 14 2026
Summit Therapeutics’ ivonescimab (HARMONi) BLA has a FDA PDUFA goal action date of November 14 2026 for non‑small cell lung cancer.
Read article →OPEC to Hold 42nd Ministerial Meeting on 29 November 2026
OPEC and non‑OPEC participating countries will convene on 29 Nov 2026 for the 42nd Ministerial Meeting, reaffirming the current crude‑oil production framework.
Read article →U2’s 16th Studio Album ‘Carnaval De Luz’ Set for November 13, 2026 Release
Island Records confirms U2’s new album ‘Carnaval De Luz’ will drop on November 13, 2026, marking their first studio album of new material in nine years.
Read article →Prediction markets express uncertainty, not established outcomes. OdinSignal uses virtual credits with no cash value.